Enzo Biochem Life Sciences Unit Awarded Patent for Increasing Detectability of Proteins and Pathogens
News May 12, 2009
Enzo Biochem, Inc. announces that its subsidiary, Enzo Life Sciences, Inc., has been granted a new patent by the U.S. Patent and Trademark Office that will complement existing proprietary technologies that have applications in the molecular diagnostics and life sciences marketplaces.
“The addition of this patent to our growing intellectual property portfolio adds to the growing line of products and technology we are providing to the medical research establishment worldwide,” said Elazar Rabbani, Ph.D., Chairman and CEO, and the lead inventor on the patent. “These patents have applications that can potentially enhance the visualization of minute quantities of biological material, which in turn, can lead to more sensitive diagnostic assays.”
Patent #7,514,551 entitled “Multisignal Labeling Reagents and Processes and Uses Therefor”, covers the use of labeled nucleotides that when linked to other biological molecules such as proteins, provide enhanced signals and solubility, thus rendering them more readily detectable. Such technology can have wide ranging uses in the development of next generation of diagnostic kits.
Chinese researchers have developed interfacially polymerized porous polymer particles for low- abundance glycopeptide separation. These polymer particles - with hydrophilic-hydrophobic heterostructured nanopores - can separate low-abundance glycopeptides from complex biological samples with high-abundance background molecules efficiently.